Faced with the end stage of heart disease, the current treatments only slow worsening of heart failure. Stem cells have the potential of self-renewal and differentiation. It is expected to replace and repair damaged myocardium. But many clinical trials have shown that the stem cell therapy of heart failure is modest or not effective. The possible causes for the limited effects of stem cell in curing heart failure are the stem cells which have been transplanted into the ischemic heart muscle may suffer low survival rate, affected by inflammatory molecules, proapoptotic factor, and lack of nutrients and oxygen, and then the stem cells which home and have been completely transplanted to the site of myocardial infarction become very small. Therefore, through preconditioning of stem cells and appropriate choice of genes for mesenchymal stem cell modification to improve the survival rate of stem cells, ability in homing and promoting angiogenesis may become the newly effective strategies for the application of stem cells therapy in heart failure. 1. Introduction With the changes in lifestyle and aging of population, the morbidity of hypertension, coronary heart disease, and other common cardiovascular disease has shown a continuous rising tendency. As the end stage of cardiovascular disease, heart failure suffers high morbidity and poor prognosis. Heart failure was mentioned on 277？193 death certificates and was the underlying cause in 56 565 of those deaths in the United States in 2007 [1, 2]. According to a random sampling survey to 15,518 residents aging from 35 to 74 in China in 2003, the prevalence of heart failure was 0.9%. It was lower than developed countries. However, the total prevalence was still up to 4,000,000, and the incidence was increasing ceaselessly [3]. Current drug treatment can only improve symptoms without preventing the ventricular remodeling and the deterioration of progressive heart function. Heart transplantation is an effective means of treating patients with heart failure. But the vast majority of patients are restricted by the age, the donor, surgical complications, medical costs, and so forth. Stem cells are the origin cells of various mature cells. They have the potential of self-renewal and differentiation. Either immediately after isolation or after expansion in vitro, stem cells are transplanted into a specific region of the heart, and ultimately replace, repair the myocardial necrosis or pathological cells; then the aim of curing heart failure can be achieved and it has brought a bright prospect for the treatment of heart
J. Lloyd, “Executive summary: heart disease and stroke statistics-2010 update: a report from the American heart association,” Circulation, vol. 121, pp. 948–954, 2010.
J. Lloyd, “Executive summary: heart disease and stroke statistics-2010 update: a report from the American heart association,” Circulation, vol. 121, no. 12, p. E259, 2010.
D. F. Gu, G. Y. Huang, J. He, et al., “Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 31, no. 1, pp. 3–6, 2003.
R. Sanz-Ruiz, E. Gutierrez Ibanes, A. V. Arranz, et al., “Phases I-III clinical trials using adult stem cells,” Stem Cells International, vol. 2010, Article ID 579142, 2010.
S. Durrani, M. Konoplyannikov, M. Ashraf, and K. H. Haider, “Skeletal myoblasts for cardiac repair,” Regenerative Medicine, vol. 5, no. 6, pp. 919–932, 2010.
K. J. Osterziel, “Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1 year results of the REPAIR-AMI trial,” European Heart Journal, vol. 28, no. 5, p. 638, 2007.
B. E. Strauer, M. Yousef, and C. M. Schannwell, “The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heart failure: the STAR-heart study,” European Journal of Heart Failure, vol. 12, no. 7, pp. 721–729, 2010.
S. L. Chen, W. W. Fang, F. Ye et al., “Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction,” American Journal of Cardiology, vol. 94, no. 1, pp. 92–95, 2004.
V. Sch？chinger, S. Erbs, A. Els？sser et al., “Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial,” European Heart Journal, vol. 27, no. 23, pp. 2775–2783, 2006.
K. Lunde, S. Solheim, S. Aakhus et al., “Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction,” New England Journal of Medicine, vol. 355, no. 12, pp. 1199–1209, 2006.
J. Ge, Y. Li, J. Qian et al., “Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI),” Heart, vol. 92, no. 12, pp. 1764–1767, 2006.
G. P. Meyer, K. C. Wollert, J. Lotz et al., “Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial,” European Heart Journal, vol. 30, no. 24, pp. 2978–2984, 2009.
S. Janssens, C. Dubois, J. Bogaert et al., “Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial,” Lancet, vol. 367, no. 9505, pp. 113–121, 2006.
J. Meluzín, J. Mayer, L. Groch et al., “Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function,” American Heart Journal, vol. 152, no. 5, pp. 975.e9–975.e15, 2006.
H. V. Huikuri, K. Kervinen, M. Niemel？ et al., “Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction,” European Heart Journal, vol. 29, no. 22, pp. 2723–2732, 2008.
M. Plewka, M. Krzemińska-Paku？a, P. Lipiec et al., “Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction,” American Journal of Cardiology, vol. 104, no. 10, pp. 1336–1342, 2009.
M. Tendera, W. Wojakowski, W. Ruzyllo, et al., “Intracoronary infusion of bone marrow-derived selected CD34(+)CXCR4(+) cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre myocardial regeneration by intracoronary infusion of selected population of stem cells in acute myocardial infarction (REGENT) trial,” European Heart Journal, vol. 30, no. 11, pp. 1313–1321, 2009.
J. W？hrle, N. Merkle, V. Mail？nder et al., “Results of intracoronary stem cell therapy after acute myocardial infarction,” American Journal of Cardiology, vol. 105, no. 6, pp. 804–812, 2010.
L. Sun, T. Zhang, X. Lan, and G. Du, “Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: a meta-analysis,” Clinical Cardiology, vol. 33, no. 5, pp. 296–302, 2010.
Y. Bai, T. Sun, and P. Ye, “Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis,” Ageing Research Reviews, vol. 9, no. 4, pp. 418–423, 2010.
C. Bearzi, M. Rota, T. Hosoda et al., “Human cardiac stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 35, pp. 14068–14073, 2007.
A. Leri, J. Kajstura, and P. Anversa, “Cardiac stem cells and mechanisms of myocardial regeneration,” Physiological Reviews, vol. 85, no. 4, pp. 1373–1416, 2005.
C. Bearzi, A. Leri, F. Lo Monaco et al., “Identification of a coronary vascular progenitor cell in the human heart,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15885–15890, 2009.
K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
T. J. Nelson, A. Martinez-Fernandez, S. Yamada, C. Perez-Terzic, Y. Ikeda, and A. Terzic, “Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells,” Circulation, vol. 120, no. 5, pp. 408–416, 2009.
M. Ieda, J. D. Fu, P. Delgado-Olguin et al., “Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors,” Cell, vol. 142, no. 3, pp. 375–386, 2010.
R. Madonna and R. De Caterina, “Adipose tissue: a new source for cardiovascular repair,” Journal of Cardiovascular Medicine, vol. 11, no. 2, pp. 71–80, 2010.
M. D. Duckers, “Treating heart attack with fat-derived stem cells may be safe in humans be safe in humans,” American Heart Association Meeting Report, p. P6021, 2010, abstract no. 12225.
C. E. Murry, M. H. Soonpaa, H. Reinecke et al., “Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts,” Nature, vol. 428, no. 6983, pp. 664–668, 2004.
J. Kajstura, M. Rota, B. Whang et al., “Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion,” Circulation Research, vol. 96, no. 1, pp. 127–137, 2005.
R. Uemura, M. Xu, N. Ahmad, and M. Ashraf, “Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling,” Circulation Research, vol. 98, no. 11, pp. 1414–1421, 2006.
U. Testa, G. Pannitteri, and G. L. Condorelli, “Vascular endothelial growth factors in cardiovascular medicine,” Journal of Cardiovascular Medicine, vol. 9, no. 12, pp. 1190–1221, 2008.
Y. L. Tang, Q. Zhao, X. Qin et al., “Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction,” Annals of Thoracic Surgery, vol. 80, no. 1, pp. 229–237, 2005.
Y. Y. Du, S. H. Zhou, T. Zhou et al., “Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction,” Cytotherapy, vol. 10, no. 5, pp. 469–478, 2008.
C. Stumpf, K. Seybold, S. Petzi et al., “Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction,” European Journal of Heart Failure, vol. 10, no. 8, pp. 733–739, 2008.
Y. Onai, J. I. Suzuki, Y. Maejima et al., “Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 292, no. 1, pp. H530–H538, 2007.
T. Kinnaird, E. Stabile, S. M. Burnett et al., “Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms,” Circulation, vol. 109, no. 12, pp. 1543–1549, 2004.
S. Ohnishi, H. Sumiyoshi, S. Kitamura, and N. Nagaya, “Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions,” FEBS Letters, vol. 581, no. 21, pp. 3961–3966, 2007.
Y. L. Tang, Y. Tang, Y. C. Zhang, K. Qian, L. Shen, and M. I. Phillips, “Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector,” Journal of the American College of Cardiology, vol. 46, no. 7, pp. 1339–1350, 2005.
S. I. Hodgetts, M. W. Beilharz, A. A. Scalzo, and M. D. Grounds, “Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or NK1.1+ cells,” Cell Transplantation, vol. 9, no. 4, pp. 489–502, 2000.
M. Hofmann, K. C. Wollert, G. P. Meyer et al., “Monitoring of bone marrow cell homing into the infarcted human myocardium,” Circulation, vol. 111, no. 17, pp. 2198–2202, 2005.
J. K. Won, H. J. Kang, H. S. Kim, J. K. Chung, C. L. Myung, and S. L. Dong, “Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1295–1301, 2006.
X. Hu, S. P. Yu, J. L. Fraser et al., “Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis,” Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799–808, 2008.
M. Kubo, T. S. Li, R. Suzuki et al., “Hypoxic preconditioning increases survival and angiogenic potency of peripheral blood mononuclear cells via oxidative stress resistance,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 294, no. 2, pp. H590–H595, 2008.
Y. L. Tang, W. Zhu, M. Cheng et al., “Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression,” Circulation Research, vol. 104, no. 10, pp. 1209–1216, 2009.
Z. Pasha, Y. Wang, R. Sheikh, D. Zhang, T. Zhao, and M. Ashraf, “Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium,” Cardiovascular Research, vol. 77, no. 1, pp. 134–142, 2008.
M. R. Afzal, H. K. Haider, N. M. Idris, S. Jiang, R. P. H. Ahmed, and M. Ashraf, “Preconditioning promotes survival and angiomyogenic potential of mesenchymal stem cells in the infarcted heart via NF-κB signaling,” Antioxidants and Redox Signaling, vol. 12, no. 6, pp. 693–702, 2010.
Y. J. Yang, H. Y. Qian, J. Huang et al., “Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 12, pp. 2076–2082, 2009.
R. X. Xu, J. Chen, X. F. Cong, S. Hu, and X. Chen, “Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2,” Journal of Cellular Biochemistry, vol. 103, no. 1, pp. 256–269, 2008.
W. Zhang, X. Su, Y. Gao et al., “Berberine protects mesenchymal stem cells against hypoxia-induced apoptosis in vitro,” Biological and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1335–1342, 2009.
W. Li, N. Ma, L. L. Ong et al., “Bcl-2 engineered MSCs inhibited apoptosis and improved heart function,” Stem Cells, vol. 25, no. 8, pp. 2118–2127, 2007.
S. Y. Lim, Y. S. Kim, Y. Ahn et al., “The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model,” Cardiovascular Research, vol. 70, no. 3, pp. 530–542, 2006.
J. Yang, W. Zhou, W. Zheng et al., “Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction,” Cardiology, vol. 107, no. 1, pp. 17–29, 2006.
Z. J. Yang, D. C. Ma, W. Wang et al., “Experimental study of bone marrow-derived mesenchymal stem cells combined with hepatocyte growth factor transplantation via noninfarct-relative artery in acute myocardial infarction,” Gene Therapy, vol. 13, no. 22, pp. 1564–1568, 2006.
L. Sun, M. Cui, Z. Wang et al., “Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction,” Biochemical and Biophysical Research Communications, vol. 357, no. 3, pp. 779–784, 2007.
Q. Yin, P. Jin, X. Liu et al., “SDF-1α inhibits hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells through PI3K/Akt and ERK1/2 signaling pathways,” Molecular Biology Reports, vol. 38, no. 1, pp. 9–16, 2010.
Z. Cheng, L. Ou, X. Zhou et al., “Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance,” Molecular Therapy, vol. 16, no. 3, pp. 571–579, 2008.
V. H. Fan, K. Tamama, A. Au et al., “Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells,” Stem Cells, vol. 25, no. 5, pp. 1241–1251, 2007.
C. Bao, J. Guo, G. Lin, M. Hu, and Z. Hu, “TNFR gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following MI,” Scandinavian Cardiovascular Journal, vol. 42, no. 1, pp. 56–62, 2008.
T. M. Yau, C. Kim, G. Li, Y. Zhang, R. D. Weisel, and R. K. Li, “Maximizing ventricular function with multimodal cell-based gene therapy,” Circulation, vol. 112, no. 9, pp. I123–I128, 2005.
J. Shujia, H. K. Haider, N. M. Idris, G. Lu, and M. Ashraf, “Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair,” Cardiovascular Research, vol. 77, no. 3, pp. 525–533, 2008.
